# SPY001 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/spy001

> The next catalyst for SPY001, sponsored by Spyre Therapeutics, Inc. (SYRE), is its primary completion, June 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SPY001 |
| Codes | SPY001, SPY001-001 |
| Sponsor | Spyre Therapeutics, Inc. (SYRE) https://sec-api.dev/companies/syre/catalysts |
| Indications | moderate-to-severely active uc, [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jun 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-27, last confirmed 2025-05-08.
- SEC Form 10-Q (accession 0001636282-25-000049): "We initiated a Phase 1 clinical trial in healthy volunteers of SPY001 and announced the dosing of our first participant in June 2024." https://www.sec.gov/Archives/edgar/data/1636282/000163628225000049/syre-20250331.htm
- SEC Form 10-K (accession 0001636282-25-000020): "We initiated a Phase 1 clinical trial in healthy volunteers of SPY001 and announced the dosing of our first participant in June 2024." https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2024-11-12, last confirmed 2025-01-13.
- SEC Form 8-K (accession 0001628280-24-046860): "Based on these data, and subject to regulatory feedback, the Company plans to initiate a Phase 2 platform trial in mid-2025 that is expected to ultimately include SPY001, SPY002 (TL1A), SPY003 (IL-23) and combinations thereof." https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/syre-20241112.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-24-046860): "Company plans to initiate a platform Phase 2 trial in mid-2025 that will include SPY001, followed by SPY002 (TL1A), SPY003 (IL-23), and combinations thereof, providing three optimized monotherapy readouts and three potentially paradigm-changing combination readouts under an efficient single master protocol" https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/exhibit991-8xkdatarelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-24-046860): "Based on these data, and subject to regulatory feedback, the Company plans to initiate a Phase 2 platform trial in mid-2025 that will ultimately include SPY001, SPY002 (TL1A), SPY003 (IL-23) and" https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/exhibit991-8xkdatarelease.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-005015): "Initiation of Phase 2 proof-of-concept study in UC patients in mid-2025 with target exposures that have the potential to increase or accelerate efficacy" https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348dex991.htm

### mid-2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-02-27, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001636282-25-000050): "•Based on these interim results, Spyre plans to advance SPY001 to a Phase 2 clinical trial in UC patients in mid-2025." https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001636282-25-000022): "Based on these interim results, Spyre plans to advance SPY001 to a Phase 2 clinical trial in UC patients in mid-2025." https://www.sec.gov/Archives/edgar/data/1636282/000163628225000022/spyre-20241231xexx991.htm
- SEC Form 10-Q (accession 0001636282-25-000049): "Based on these interim results, we plan to advance SPY001 to a Phase 2 clinical trial in UC patients in mid-2025." https://www.sec.gov/Archives/edgar/data/1636282/000163628225000049/syre-20250331.htm
- SEC Form 10-K (accession 0001636282-25-000020): "Based on these interim results, we plan to advance SPY001 to a Phase 2 clinical trial in UC patients in mid-2025." https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm

### April 13, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: moderate-to-severely active UC.
- First seen 2026-04-13, last confirmed 2026-04-16.
- SEC Form 8-K (accession 0001628280-26-024831): "On April 13, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC." https://www.sec.gov/Archives/edgar/data/1636282/000162828026024831/syre-20260413.htm
- SEC prospectus (424B) (accession 0001628280-26-025310): "On April 13, 2026, we announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC." https://www.sec.gov/Archives/edgar/data/1636282/000162828026025310/spyre-finalprosuppwithpfws.htm

### Sep 2026: topline data readout

- Status: scheduled. Date confidence: month.
- First seen 2026-05-05, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001636282-26-000098): "Enrollment for Part A has completed, with SPY001 and SPY002 Part A topline induction data announced in Q2 2026, and topline data expected for SPY003 in September 2026." https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm
- SEC Form 10-Q (accession 0001636282-26-000096): "Enrollment for Part A has completed, with initial SPY001 and SPY002 Part A topline induction data announced in April 2026 and June 2026, respectively, and with SPY003 topline induction data expected in September 2026." https://www.sec.gov/Archives/edgar/data/1636282/000163628226000096/syre-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001636282-26-000051): "Enrollment for Part A has completed, with SPY001 Part A topline induction data announced in April 2026, and topline data expected for SPY002 and SPY003 in mid-2026 and the third quarter of 2026, respectively." https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/spyre-20260331xexx991.htm
- SEC Form 10-Q (accession 0001636282-26-000050): "Enrollment for Part A has completed, with initial SPY001 Part A topline induction data announced in April 2026, and initial topline data expected for SPY002 and SPY003 in mid-2026 and the third quarter of 2026, respectively." https://www.sec.gov/Archives/edgar/data/1636282/000163628226000050/syre-20260331.htm

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07012395 (A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07012395

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07012395 (A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07012395

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07652294 (Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07652294

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07652294 (Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07652294

## Same indication

- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/spy001.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SPY001 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/spy001

```bibtex
@misc{secapidev_pdufa_spy001_20261116,
  title        = {SPY001 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/spy001}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_spy001_20261116","title":"SPY001 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/spy001","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
